Showing 1136 results
-
Press release /Cosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)…
-
Press release /Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
-
Press release /Novartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights…
-
Press release /Ultibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to…
-
Press release /New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide®* to Ultibro® Breezhaler® improved lung function and was well tolerated. The FLASH…
-
Story /When Carl was diagnosed with metastatic prostate cancer, he and his wife Arlene began navigating his cancer journey while still looking to enjoy their retirement – hoping to remain active with family and friends in their retirement community.
-
Press release /Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will…
-
Press release /Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of…
-
Press release /Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and…
-
Press release /Monitoring disease activity and treatment effectiveness in MS patients in real-time is a serious challenge for physicians New data show how the use of two central nervous system-derived…